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Human Metapneumovirus as a 
Cause of Community-Acquired 
Respiratory Illness
Joanne Stockton,* Iain Stephenson,† Douglas Fleming,‡ and Maria Zambon*1
Human metapneumovirus (HMPV) is a recently identified Paramyxovirus first isolated from hospitalized
children with acute respiratory tract infections (ARTI). We sought evidence of HMPV infection in patients
who had visited general practitioners, had influenzalike illnesses (ILI), and had negative tests for influenza
and Human respiratory syncytial virus (HRSV). As part of national virologic surveillance, sentinel general
practices in England and Wales collected samples from patients of all ages with ILI during winter 2000–01.
Reverse transcriptase-polymerase chain reaction (PCR) for HMPV, influenza A (H1 and H3), influenza B,
and HRSV (A and B) was used to screen combined nose and throat swabs. PCR products from the HMPV-
positive samples were sequenced to confirm identity and construct phylogenetic trees. Of 711 swabs sub-
mitted, 408 (57.3%) were negative for influenza and HRSV; HMPV was identified in 9 (2.2%) patients.
HMPV appears to be associated with community-acquired ARTI. The extent of illness and possible compli-
cations related to this new human virus need to be clarified.
espite control of many infectious diseases in the industri-
alized world, acute viral respiratory tract infections
(ARTI) remain a leading cause of illness. Although usually
self-limiting in healthy adults, these infections are responsible
for a substantial loss of productive time and are important fac-
tors in the illness and death of the elderly population. Various
genetically diverse viruses, often with multiple types, may
cause respiratory illness; of these, influenza receives the great-
est attention (1). Human respiratory syncytial virus (HRSV) is
also increasingly implicated as an important pathogen (2).
The association between the incidence of ARTI and excess
winter deaths in the United Kingdom is well recognized (1).
Regression modeling associates excess winter deaths with
influenza and HRSV but also suggests that other pathogens
may be involved (3).
Studies of the impact of respiratory virus infections are
limited by difficulty in distinguishing respiratory pathogens
clinically and in the laboratory (4,5). Despite improved sensi-
tivity with diagnostic techniques such as reverse transcriptase-
polymerase chain reaction (RT-PCR), approximately 40% of
specimens from patients with community-acquired respiratory
illnesses during peak winter months contain no identified viral
pathogen (2,5,6). 
A new pneumovirus, Human Metapneumovirus (HMPV),
has recently been isolated in the Netherlands (7). The Pneu-
movirinae subfamily is classified into Pneumovirus, contain-
ing HRSV, and Metapneumovirus genera. In 2001, Van den
Hoogen et al. (7) reported the detection of HMPV in nasopha-
ryngeal aspirates taken in a 10-year period from 28 hospital-
ized children and infants with respiratory tract infections who
had signs and symptoms similar to those of HRSV infection. 
Establishing sensitive methods for virus detection helps to
clarify the relative contribution of different pathogens to the
extent of illness in the community. This information is impor-
tant for future development of specific antiviral therapies and
vaccines. We examined specimens submitted from patients
seen in general practice with influenzalike illnesses (ILI) dur-
ing winter 2000–01 to detect HMPV as a possible cause of
influenza- and HRSV-negative ILI.
Materials and Methods
Sentinel General Practice Networks
Clinical episodes of ILI are recorded by continuous moni-
toring in approximately 75 sentinel practices in England and
Wales, covering a population of 700,000. New episodes of ill-
ness are noted and weekly returns submitted to the Royal Col-
lege of General Practitioners research unit. ILI was defined as
symptoms of fever, cough, and muscle pains with duration of
<5 days (8,2). Virologic surveillance of ILI is performed by a
subset of the sentinel practices. Combined nose and throat
swabs are taken from persons diagnosed with ILI at the time
they see a clinician, which is often several days after onset of
illness. Swabs are mailed in virus transport medium to the
Central Public Health Laboratory for analysis. Samples are
divided into aliquots, labeled, and then frozen at -80°C on
receipt. 
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JS performed the polymerase chain reaction analysis and designed the
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HRSV and Influenza Detection
Detection of HRSV and influenza was performed prospec-
tively on receipt of samples by using multiplex PCR as previ-
ously described (2,8). 
HMPV Detection
Stored nucleic acid from 348 samples negative for influ-
enza and HRSV was analyzed by using a PCR for HMPV (7).
No optimization of the PCR detection was undertaken. Detec-
tion of HPMV was based on primers located in the L gene. For
a further 60 (14.8%) samples from which the nucleic acid
stored was insufficient, an aliquot of the original clinical mate-
rial was re-extracted by using a Magnapure (Roche Diagnos-
tics GmbH, Mannheim, Germany) automated extraction
machine according to the manufacturer’s instruction; RT was
performed as described previously (8). Twenty microliters of
cDNA was added to 80 µL of reaction mix, which yielded a
final concentration of 20 mM Tris-HCl pH8.4, 10 mM MgCl2,
50 mM KCl, and 3 U Taq polymerase and 50 pmol of each
primer. Amplification, using a DNA Engine thermocycler (MJ
Research, Essex, England), consisted of 1 cycle at 94°C for 2
min, followed by 35 cycles of 94°C 1 min, 58°C 1 min, and
72°C for 1 min. Amplicons of the expected size (171 bp) were
visualized by agarose gel electrophoresis. PCR sensitivity was
determined by cloning of the PCR product into TOPO PCR4
vector (Invitrogen Corp., San Diego, CA) according to the
manufacturer’s instructions. Plasmid preparations were per-
formed by using a Qiagen minprep kit (QIAGEN, Inc., Valen-
cia, CA), according to the manufacturer’s instructions. DNA
quantitation followed by PCR, using the original primers and
conditions (as above) with the addition of 0.1 mM of each
deoxynucleoside triphosphate per reaction, was undertaken
using the plasmid plus insert as template. Total RNA at the
time of extraction was estimated by spectrophotometry at
A260.
The resulting amplicons were sequenced by using a Ceq
Dye terminator sequencing kit (Beckman Coulter, Inc., Somer-
set, NJ) according to the manufacturer’s instructions.
Sequenced reactions were run on a CEQ 2000 capillary
sequencer (Beckman Coulter). Resulting sequence was
BLAST searched; 98% identity to deposited sequences of
HMPV was seen.
Phylogenetic Analysis
Sequences were aligned by using the program Megalign
(Lasergene, DNA STAR, Inc., Madison, WI) and exported into
PAUP* (URL: http://paup.csit.fsu.edu/about.html). Maximum
likelihood trees were created by using the K81 model of evolu-
tion and bootstrapped x1000. 
Results
ILI Clinical Diagnosis
A total of 711 swabs were submitted from cases of ILI seen
at the subgroup of 16 sentinel practices supplying virologic
specimens. These cases constituted approximately 65% of the
total consultations of ILI in some of these practices from Octo-
ber 1, 2000, through March 30, 2001, covering a population of
241,000. Swabs were obtained from all age groups: 79 (11%)
from those <5 years; 115 (16%) from those 5–14.9 years; 300
(42%) from those 15–39.9 years; 179 (25%) from those 40–
64.9 years; and 37 (5%) from those >65 years; for 1 sample the
age was unknown.
HMPV PCR Sensitivity
The sensitivity of the PCR was determined to be at least 1
femtogram of DNA template and 0.32 µg of a total RNA prep-
aration.
HMPV
A total of 408 specimens were negative for influenza and
HRSV; of these, 405 (99.3%) samples were available for anal-
ysis and examined for HMPV by RT-PCR. Nine (2.2%) of
these were positive for HMPV by PCR. Samples were unre-
lated geographically or epidemiologically. Clinical history and
findings are summarized in the Table. HMPV was detected in
samples from a child <1 year old, from four persons ages 18–
64 years, and four persons ages >65 years. Six (67%) of the
nine had clinical evidence of lower respiratory tract involve-
ment. Four (44%) received antibiotic therapy at the time they
were seen by a clinician. All made a complete recovery. Figure
1 shows timing of HMPV-positive sample collection relative
to the circulation of HRSV and influenza, and the rate of clini-
cal ILI consultations throughout the study period. 
HMPV Phylogeny
The phylogenetic analysis of the L gene sequences from
our patients and nine previously reported (7) showed at least
two possible clusters of sequences. The sequences obtained
from the adult patients cluster with those obtained from
children from our study and those previously reported (7) (Fig-
ure 2). 
Discussion
The extent of illness in the community caused by circulat-
ing respiratory viruses is currently underestimated. Problems
in diagnosing these viruses include capture of suitable speci-
mens for virologic diagnosis, limitations caused by transport
of labile viruses, and sampling from adult subjects, who may
shed fewer viruses than children (9). However, PCR is more
sensitive for detecting a range of respiratory viruses than are
culture or serologic methods and has been shown to be a
robust diagnostic tool (10).
We have found evidence of HMPV in approximately 2.2%
of cases of ILI that were negative for HRSV and influenza. If
no other HMPV were detected in the rest of the samples (i.e.,
as a dual infection with either HRSV or influenza), the overall
detection rate in this population would be 1.3% with the use of
the PCR method. We cannot exclude the possibility that
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tract and is of no clinical importance, nor the possibility of
dual infection. Our estimate, therefore, is likely to be a mini-
mum one. Respiratory virus coinfections appear to occur at a
rate of 1% to 3% in various sample sets (2,11). Nonetheless, as
the specimens are taken from symptomatic patients seeking
medical consultation at the time of respiratory illness, the
assumption that the pathogen detected is responsible for the
illness is reasonable. 
When HMPV was first isolated, it was associated with
symptoms of ARTI in infants and children similar to those
seen in HRSV infection, which ranged in severity from self-
limiting mild respiratory illness to respiratory failure requiring
ventilation. Therefore, diagnosing HMPV infection and differ-
entiating it from other respiratory viruses may be impossible
on clinical grounds alone. All the specimens were negative for
other respiratory viruses, and it was concluded that HMPV
was likely to be the responsible pathogen. 
Our results are consistent with the association of HMPV
with acute respiratory infections in winter (7) and demonstrate
that this virus is associated with at a least a proportion of mild,
community-acquired, self-limiting respiratory illnesses in all
age groups. Initial seroprevalence data documented that all
children were seropositive by 5 years of age (7), and our
results imply that, like HRSV, HMPV is capable of causing
clinically important reinfection in late childhood or adult life.
We consider that our data on the prevalence of HMPV in a
sentinel physician surveillance scheme, used for combined
clinical-virologic monitoring, are likely to be a minimum esti-
mate of this virus’ contribution to acute respiratory infections,
for several reasons. Our detection strategy depends on the use
of PCR targets in the L gene of a paramyxovirus and has been
determined by sequence availability. A limitation of the cur-
rent study may be the sensitivity of the PCR used. Although
the sensitivity was determined for a DNA target and total RNA
preparation, no information is currently available, for compar-
ison, on the sensitivity of the PCRs that other studies have
used (12,13). Nethertheless, we consider these estimates may
be taken as a robust minimum value. A differential gene tran-
scription present in the Paramyxoviridae as a whole suggests
that targeting diagnostics to genes that are transcribed more
proximally may be a more sensitive approach. As virus quanti-
tiation methods are developed and in vitro transcription meth-
ods are established, determination of copy number sensitivity
will become possible. Currently, no methods for virus quanti-
tation in cell culture are established, and the full genome
sequence has only very recently been published (14). Further-
more, no information exists on the efficiency of HMPV detec-
tion directly from nose and throat swab specimens, without
culture amplification as was done in the Dutch study (7). As
only patients presenting with ILI symptoms were sampled in
this surveillance cohort, most acute respiratory infections that
occur outside this surveillance definition are unsampled,
thereby increasing the likelihood of underestimation of HMPV
as a cause of all respiratory infections. Since sampling only
occurs during the winter season (October–March), we cannot
Table. Clinical information on patients with influenzalike illness and positive Metapneumovirus polymerase chain reaction results, 
seen by general practitionersa
Sex Age (yr) Past medical history Influenza vaccine Clinical signs and symptoms (days symptoms persist/total days ill)
F 46 None No (7/7) febrile respiratory symptoms, sore throat, malaise, and lethargy. Chest clear
F 20 None No (2/7) sore throat, unproductive cough, sternal pain, wheeze. Signs: 37.4°C; chest clear
M 1 None No (4/7) coughing, vomiting. OE: 37.2°C, chest and abdomen normal
F 75 Mild hypertension Yes (4/7) febrile respiratory illness, cough. Signs: 37.4°C, bilateral basal crackles
F5 7 C O P D b Yes (5/7) coryza, sore throat, thick green sputum. Signs: poor air entry and bilateral crackles
M 65 Mild hypertension No (3/7) cough, upper respiratory symptoms. Chest clear
F 73 None Yes (6/7) cough, green sputum, and dyspnea
M7 4 C O P D ,  IHD Yes (5/7) cough, malaise, sputum, breathlessness
M 46 None No (6/7) days sore throat, sputum, wheeze, breathlessness
Signs: PEFRb 260 mL/min, wheeze
aAll made a full recovery.
bCOPD, chronic obstructive pulmonary disease; IHD, ischemic heart disease; OE, on examination; PEFR, peak expiratory flow rate.
Figure 1. Incidence of influenzalike illness consultations in England dur-
ing winter 2000–01 and timing of collection of positive samples for
human Metapneumovirus (HMPV). HRSV, Human respiratory syncytial
virus; PCR, polymerase chain reaction; RCGP, Royal College of Gen-
eral Practitioners. RCGP index is the consultation rate per 100,000 of
the population for ILI.RESEARCH
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determine whether the virus circulates year-round or whether
it has seasonal peaks during the summer or winter months.
Clearly, HMPV cocirculates with influenza and HRSV (Figure
1, data from this national surveillance program published on
the PHLS web [URL: http://www.phls.co.uk/topics_az/influ-
enza/Activity0102/graph12.pdf]), which adds to the potential
for clinical diagnostic confusion.
Four out of five ILI cases in adults <65 years of age or with
cardiorespiratory conditions in which HMPV was detected
occurred in persons who had received influenza vaccination in
accordance with national vaccination policy. This finding indi-
cates that HMPV infection may cause an illness difficult to
distinguish from influenza in the elderly and may be one of the
reasons for underestimating the clinical efficacy of influenza
vaccine in the elderly when clinical endpoints are used.
Sequencing analysis was performed on seven out of nine
of our isolates by using primers that amplify a portion of the L
gene. By analogy with other paramyxoviruses, the L gene
codes for the viral polymerase. This gene typically shows less
variability than genes coding for surface proteins. These
results are consistent with the limited published evidence for
genetic variation between HMPV isolates, suggesting the pos-
sibility of more than one type (7). Analysis of the structural
membrane proteins that are more commonly associated with
genetic or antigenic drift may identify further variability.
Accurately determining relationships between strain clusters
may also require sequencing of larger portions of the genome.
This study has identified, for the first time, HMPV in
adults and children in the community. Phylogenetic analysis
confirmed that similar strains are circulating in adults and chil-
dren at the same time, a feature also seen with influenza and
HRSV infection (2).
More sensitive diagnostic tools need to be developed to
ascertain a true estimate of the extent of illness caused by
HMPV in the general community.
Although ILI and ARTI are common illnesses and usually
self-limiting in healthy persons, these infections have a major
impact on the overall health of the population with substantial
loss of productive time. Continuous surveillance of respiratory
pathogens is important for public health. Assessing the role of
individual pathogens is important for the potential develop-
ment of vaccines and for considering specific antiviral therapy.
In the future, we will consider including HMPV detection in
our routine surveillance programs of respiratory illness.
Whether this interesting new virus, HMPV, plays a major clin-
ical role in winter hospital admissions and excess deaths in dif-
ferent age groups of the general population remains to be seen. 
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